Publications by authors named "S Tenhola"
Health-related quality of life in boys with constitutional delay of growth and puberty.
Front Endocrinol (Lausanne)
December 2022
Article Synopsis
- Constitutional delay of growth and puberty (CDGP) is a common cause of delayed puberty in healthy boys, often leading to psychosocial issues that may warrant medical treatment.* -
- A study involving 22 boys with CDGP compared the effects of treatments (aromatase inhibitor letrozole vs. testosterone) on their health-related quality of life (HRQoL) over 12 months, using a validated 16D assessment tool.* -
- Results showed that while CDGP boys had similar overall HRQoL scores to their peers initially, they were less satisfied with their physical appearance; after treatment, their appearance satisfaction significantly improved, aligning their HRQoL with that of age-matched boys.*
Context: Circulating levels of liver-enriched antimicrobial peptide 2 (LEAP2), a ghrelin receptor antagonist, decrease under caloric restriction and increase in obesity. The role of LEAP2 in male puberty, a phase with accelerated energy demand, is unclear.
Objective: This work aimed to investigate whether circulating LEAP2 levels are downregulated in boys following the onset of puberty to respond to the energy need required for growth.
Objective: The influence of androgens and oestrogens on growth is complex, and understanding their relative roles is important for optimising the treatment of children with various disorders of growth and puberty.
Design: We examined the proportional roles of androgens and oestrogens in the regulation of pubertal growth in boys with constitutional delay of growth and puberty (CDGP). The study compared 6-month low-dose intramuscular testosterone treatment (1 mg/kg/month; n = 14) with per oral letrozole treatment (2.
Objective: Congenital hypogonadotropic hypogonadism (CHH) is associated with impaired bone mineral density in adulthood, whereas the estimates on bone structure in adolescents with CHH has not been previously evaluated. This study describes bone structure in CHH patients and compares it to that in boys with constitutional delay of growth and puberty (CDGP).
Design: A cross-sectional study.
Study Question: Does treatment of constitutional delay of growth and puberty (CDGP) in boys with aromatase inhibitor letrozole (Lz) or conventional low-dose testosterone (T) have differing effects on developing seminiferous epithelium?
Summary Answer: Anti-Müllerian hormone (AMH) declined similarly in both treatment groups, and the two Sertoli cell-derived markers (AMH and inhibin B (iB)) exhibited differing responses to changes in gonadotrophin milieu.
What Is Known Already: Boys with CDGP may benefit from puberty-inducing medication. Peroral Lz activates gonadotrophin secretion, whereas intramuscular low-dose T may transiently suppress gonadotrophins and iB.